News Search Results
Apr 02, 2026, 07:30 ET Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
the University of Pennsylvania that was a leading enroller in the Phase 3 FLASH study.About Cutaneous T-Cell Lymphoma (CTCL)CTCL is a class of non-Hodgkin's lymphoma (NHL), a type of cancer of the white blood cells that are an integral part of the immune system. Unlike most NHLs which
More news about: SOLIGENIX, INC.
Apr 02, 2026, 06:00 ET AvenCell Therapeutics Announces First Patient Dosed in Phase I QUADvance Study with AVC-203, a Novel Allogeneic CD19/CD20 Dual-Targeting CAR-T Investigational Therapy for the Treatment of Relapsed/Refractory B-Cell Malignancies
eliminate cells expressing receptors CD19 and/or CD20, which are known to be expressed in nearly all B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL). The product incorporates a novel, dimerized receptor construct combining constitutive CD19/CD20 dual-targeting with AvenCell's proprietary
More news about: AvenCell Therapeutics, Inc.
Apr 01, 2026, 16:05 ET ADC Therapeutics Announces New Employee Inducement Grant
accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy.Headquartered
More news about: ADC Therapeutics SA
Apr 01, 2026, 07:00 ET Cardinal Health expands Actinium-225 production capacity to support growing demand for novel cancer therapies
developed and are becoming an increasingly promising new class of therapies for cancers including prostate, neuroendocrine, breast, colon, melanoma, and lymphoma. Despite growing demand, worldwide clinical progress has been slowed by limited availability.Since announcing routine Ac-225 production globally
More news about: Cardinal Health
Mar 31, 2026, 11:32 ET Cell Therapy Market Size to Surpass USD 17.15 Billion by 2032, Driven by Chronic Disease Treatment and CAR-T Therapy Growth, Says New MMR Analysis
anito‑cel.In December 2025, Kite Pharma showcased encouraging Phase 1 results for next‑generation bicistronic CAR‑T therapies in relapsed/refractory B‑cell lymphoma, highlighting advanced cell therapy innovation.In February 2026, Johnson & Johnson committed over $1 billion to build a next‑generation
More news about: Maximize Market Research Pvt. Ltd.
Mar 31, 2026, 09:11 ET Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development
(Nasdaq: CTXR), today provided a commercial update on the U.S. launch of LYMPHIR™ (denileukin diftitox-cxdl) for the treatment of cutaneous T-cell lymphoma (CTCL), highlighting continued adoption across leading oncology centers, broad payer coverage progress, and advancing investigator-led clinical studies.
More news about: Citius Oncology, Inc.
Mar 31, 2026, 07:30 ET Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results
Synthetic Hypericin 2) clinical trial of HyBryte™ (SGX301 or synthetic hypericin) for the treatment of early-stage cutaneous T-cell lymphoma (CTCL) slated for the second quarter and the release of top-line results from this trial expected in the second half of 2026. The overall blinded
More news about: SOLIGENIX, INC.
Mar 27, 2026, 11:00 ET ThriveMD Announces Addition of TPE to Longevity Solutions
neurodegenerative conditions. These include Multiple Sclerosis, Guillain-Barré syndrome, Goodpasture's syndrome, Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), Myasthenia gravis, and Alzheimer's disease. While TPE isn't a cure for these and more complex health diseases, it can help alleviate symptoms and
More news about: ThriveMD
Mar 27, 2026, 10:22 ET Lisa G. Roth, MD, Named Director of Pediatric Hematology-Oncology at Hassenfeld Children's Hospital at NYU Langone
group of blood cancers that affect the immune system—in children, adolescents, and young adults. Her work focuses on several types of lymphoma, including Hodgkin lymphoma and other rare forms that can affect younger patients. Through research funded by the National Institutes of Health, she studies how
More news about: Hassenfeld Children's Hospital at NYU Langone
Mar 27, 2026, 10:00 ET AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting
immune system problems. RINVOQ may increase your risk of certain cancers. Lymphoma and other cancers, including skin cancers, can happen. Current or past smokers are at higher risk of certain cancers, including lymphoma and lung cancer. Follow your HCP's advice about having your skin checked for skin
More news about: AbbVie
Mar 26, 2026, 09:54 ET Keymed Biosciences Announces 2025 Annual Results and Business Updates
phase.CM369/ICP-B05 (CCR8 antibody) : Phase I dose-escalation trials continue in advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma.Innovative Technology Platforms Continue to Evolve, Forward-Looking Positioning in Chronic DiseaseThe company has
More news about: Keymed
Mar 26, 2026, 09:32 ET CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0
in combination with R-CHOP (Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone) for first-line treatment of Diffuse Large B-Cell Lymphoma (DLBCL) and CS5001 in combination with other SOC therapies for front-line DLBCL. Monotherapy cohorts continue to enroll patients with aggressive and
More news about: CStone Pharmaceuticals
Mar 26, 2026, 08:30 ET COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
with breast implants, ranging from autoimmune-related symptoms to the rare but serious condition of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). CollPlant's breast implants, composed of the Company's proprietary plant-derived rhCollagen and additional biomaterials, are designed
More news about: CollPlant
Mar 26, 2026, 07:30 ET Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease
HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide.
More news about: SOLIGENIX, INC.
Mar 25, 2026, 10:45 ET Veterinary Diagnostics Market Size Worth USD 19.63 Billion by 2032, Exclusive Report by Maximize Market Research
AI-Enabled BreakthroughsIn February 2026, IDEXX Laboratories Inc.: Expanded its diagnostic ecosystem with IDEXX Cancer Dx canine lymphoma and inVue Dx platforms, enhancing early disease detection and workflow efficiency. In January 2025, Zoetis Services LLC: Launched AI-powered
More news about: Maximize Market Research Pvt. Ltd.
Mar 25, 2026, 10:18 ET XtalPi Holdings Announces Full Year 2025 Annual Results
therapy achieved 100% complete remission in dozens of patients at ultra-low doses in investigator-initiated trials (IITs) for relapsed/refractory lymphoma, leukemia, and moderate-to-severe SLE. In March 2026, it received FDA IND clearance for the relevant indications. Meanwhile, META 10-TILs and multiple
More news about: XtalPi Inc.
Mar 25, 2026, 09:00 ET Clinical Data on ST-001 nanoFenretinide™ to be presented at USCLC Annual Workshop 2026
nanoFenretinide™ in Previously Treated Cutaneous T-Cell Lymphoma" which will highlight emerging data from SciTech's clinical trial evaluating ST-001 in patients with Cutaneous T-Cell Lymphoma (CTCL), a subtype of T-cell non-Hodkin lymphoma.The presentation will feature early clinical findings
More news about: SciTech Development, Inc.
Mar 24, 2026, 10:01 ET A Success Story - DelveInsight's Strategic Support to a Pharma Company in Interleukin-2 Target Patient Pool and Epidemiology-based Market Forecast Analysis
twelve target indications: Non-Segmental Vitiligo (NSV), Aplastic Anemia, Amyotrophic Lateral Sclerosis (ALS), Peripheral T-cell lymphoma (PTCL), Cutaneous T-cell lymphoma (CTCL), Ovarian cancer, Head and neck squamous cell carcinoma (HNSCC), Melanoma, Atopic Dermatitis, Alopecia Areata, Non-small cell
More news about: DelveInsight Business Research, LLP
Mar 24, 2026, 09:17 ET Belay Diagnostics Reports 82% Clinical Impact Rate for Summit™ and Vantage™ in CNS Lymphoma Study
cohort were MYD88, a hallmark of CNS lymphoma, followed by TP53 and CD79B, demonstrating that Summit can identify alterations critical to CNS lymphoma diagnosis. Aneuploidy findings were also clinically significant: several cases with concern for metastatic CNS lymphoma showed five or more aneuploidy events
More news about: Belay Diagnostics
Mar 24, 2026, 08:00 ET Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts
The United States Cutaneous Lymphoma Consortium (USCLC) Annual Workshop is widely regarded as one of the most focused scientific gatherings dedicated to cutaneous lymphomas, including cutaneous T-cell lymphoma (CTCL). The meeting brings together leading dermatologists,
More news about: Citius Oncology, Inc.
Mar 24, 2026, 07:01 ET Karyopharm Announces $30 Million Private Placement with RA Capital
targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL).Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities
More news about: Karyopharm Therapeutics Inc.
Mar 24, 2026, 07:00 ET Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction
heavily pre-treated multiple myeloma; and (iii) under accelerated approval in adult patients with diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. XPOVIO® (also known as NEXPOVIO® in certain countries) has received regulatory
More news about: Karyopharm Therapeutics Inc.
Mar 23, 2026, 07:30 ET HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026
treatment of cutaneous T-cell lymphoma (CTCL) are being presented at the United States Cutaneous Lymphoma Consortium (USCLC) Workshop (March 26, 2026), which precedes the American Academy of Dermatology (AAD) Annual Meeting. Ellen Kim, MD, Director, Penn Cutaneous Lymphoma Program, Vice Chair of Clinical
More news about: Soligenix
Mar 20, 2026, 05:06 ET Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability
List (NRDL), including XPOVIO® monotherapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and XPOVIO® in combination with dexamethasone for the treatment of R/R MM.Taiwan
More news about: Antengene Corporation Limited
Mar 19, 2026, 16:00 ET Curis Provides Fourth Quarter 2025 Business Update
Operational HighlightsTakeAim LymphomaLakshmi Nayak, MD, Director of the Center for CNS Lymphoma at Dana-Farber Cancer Institute in Boston, presented a poster with updated clinical data in Primary CNS Lymphoma (PCNSL) at the 30th Annual Meeting of
More news about: Curis, Inc.